-
Tytuł:
-
Side-Chain Selenium-Grafted Polymers Combining Antiangiogenesis Treatment with Photodynamic Therapy and Chemotherapy.
-
Autorzy:
-
Sun C; Key Laboratory of Organic Optoelectronics and Molecular Engineering, Department of Chemistry, Tsinghua University, Beijing 10084, China.
Gao S; Key Laboratory of Polyoxometalate Science of the Ministry of Education and Faculty of Chemistry, Northeast Normal University, Changchun 130024, China.
Tan Y; Key Laboratory of Organic Optoelectronics and Molecular Engineering, Department of Chemistry, Tsinghua University, Beijing 10084, China.
Zhang Z; Key Laboratory of Organic Optoelectronics and Molecular Engineering, Department of Chemistry, Tsinghua University, Beijing 10084, China.
Xu H; Key Laboratory of Organic Optoelectronics and Molecular Engineering, Department of Chemistry, Tsinghua University, Beijing 10084, China.
-
Źródło:
-
ACS biomaterials science & engineering [ACS Biomater Sci Eng] 2021 Jul 12; Vol. 7 (7), pp. 3201-3208. Date of Electronic Publication: 2021 Jun 07.
-
Typ publikacji:
-
Journal Article; Research Support, Non-U.S. Gov't
-
Język:
-
English
-
Imprint Name(s):
-
Original Publication: Washington, DC : American Chemical Society, [2015]-
-
MeSH Terms:
-
Pharmaceutical Preparations*
Photochemotherapy*
Porphyrins*
Selenium*
Cell Line, Tumor ; Human Umbilical Vein Endothelial Cells ; Humans ; Matrix Metalloproteinase 2 ; Photosensitizing Agents ; Polymers ; Selenium Oxides ; Vascular Endothelial Growth Factor A
-
Contributed Indexing:
-
Keywords: antiangiogenesis treatment; combination therapy; drug delivery; selenoxide elimination
-
Substance Nomenclature:
-
0 (Pharmaceutical Preparations)
0 (Photosensitizing Agents)
0 (Polymers)
0 (Porphyrins)
0 (Selenium Oxides)
0 (Vascular Endothelial Growth Factor A)
0 (selenoxide)
EC 3.4.24.24 (Matrix Metalloproteinase 2)
H6241UJ22B (Selenium)
-
Entry Date(s):
-
Date Created: 20210607 Date Completed: 20210802 Latest Revision: 20220531
-
Update Code:
-
20240104
-
DOI:
-
10.1021/acsbiomaterials.1c00254
-
PMID:
-
34096719
-
The abnormal tumor vasculature in solid tumors creates hypoxia and leads to compromising the delivery and anticancer efficiency of nanomedicine. Nanomaterials with intrinsic antiangiogenesis ability might normalize tumor vessels and improve the therapeutic effect of O 2 -related treatment like PDT. Herein, we designed and prepared ROS-responsive side-chain selenium-grafted polymers, which had potential antiangiogenic activity, as vehicles to load photodynamic therapeutic agent Ce6 and chemotherapeutic drug oridonin. Under NIR irradiation, the C-Se bonds on the side chain of polymers could be cleaved in the presence of 1 O 2 produced by Ce6 and further formed organic selenic acid through selenoxide elimination reaction. The generated seleninic acid could downregulate the expression of vascular endothelial growth factor (VEGF) and matrix metalloproteinase-2 (MMP-2) to inhibit angiogenesis and further relieve hypoxia. The released oridonin could significantly increase the intracellular ROS concentration. Both could modulate cancer cells' microenvironment to reinforce PDT. Therefore, these nanomedicines could be a good candidate for synergistic treatments of antiangiogenesis treatment, PDT, and chemotherapy.
